Payment overview · 2025
General Payments
$316.48
13 reported records · 6 companies
Healthcare provider profile · identity verified
Alfonso Ramirez, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · DALLAS, TX · NPI 1730158718
Verified facts
What the public records show
CMS Open Payments records show Alfonso Ramirez, M.D. received $316.48 in general payments during 2025 across 13 reported records.
PFIZER INC. accounted for 43.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $136.24 | 43.0% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $66.32 | 21.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.99 | 14.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.43 | 10.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.57 | 5.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.93 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $316.48 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $136.24 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $112.31 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.43 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $30.86 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $30.86 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 114 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
114 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
114 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 910 | 310 |
| Metformin Hcl | Metformin Hcl | 676 | 214 |
| Amlodipine Besylate | Amlodipine Besylate | 656 | 218 |
| Lisinopril | Lisinopril | 600 | 197 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 579 | 205 |
| Levothyroxine Sodium | Levothyroxine Sodium | 522 | 160 |
| Losartan Potassium | Losartan Potassium | 414 | 131 |
| Tamsulosin Hcl | Tamsulosin Hcl | 324 | 115 |
| Metoprolol Succinate | Metoprolol Succinate | 298 | 92 |
| Simvastatin | Simvastatin | 278 | 79 |
| Alendronate Sodium | Alendronate Sodium | 267 | 79 |
| Glimepiride | Glimepiride | 247 | 85 |
| Pravastatin Sodium | Pravastatin Sodium | 247 | 76 |
| Furosemide | Furosemide | 206 | 72 |
| Pioglitazone Hcl | Pioglitazone Hcl | 183 | 60 |
| Metformin Hcl Er | Metformin Hcl | 175 | 61 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 170 | 53 |
| Nifedipine Er | Nifedipine | 170 | 62 |
| Omeprazole | Omeprazole | 166 | 64 |
| Carvedilol | Carvedilol | 165 | 54 |
| Gabapentin | Gabapentin | 165 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 146 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 143 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 137 | 49 |
| Azelastine Hcl | Azelastine Hcl | 119 | 60 |
| Jardiance | Empagliflozin | 114 | 42 |
| Glipizide Er | Glipizide | 112 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 110 | 36 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 107 | 39 |
| Sertraline Hcl | Sertraline Hcl | 98 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 88 | 51 |
| Allopurinol | Allopurinol | 85 | 28 |
| Candesartan Cilexetil | Candesartan Cilexetil | 82 | 27 |
| Famotidine | Famotidine | 81 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 76 | 23 |
| Ketoconazole | Ketoconazole | 73 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 71 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 71 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 29 |
| Sucralfate | Sucralfate | 68 | 30 |
| Metolazone | Metolazone | 61 | 23 |
| Potassium Chloride | Potassium Chloride | 58 | 16 |
| Montelukast Sodium | Montelukast Sodium | 56 | 21 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 55 | 18 |
| Trazodone Hcl | Trazodone Hcl | 51 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 17 |
| Meloxicam | Meloxicam | 49 | 42 |
| Lovastatin | Lovastatin | 46 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 45 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 37 |
| Linzess | Linaclotide | 40 | 11 |
| Rybelsus | Semaglutide | 39 | 11 |
| Spironolactone | Spironolactone | 39 | 15 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 14 |
| Clonidine Hcl | Clonidine Hcl | 38 | 15 |
| Meclizine Hcl | Meclizine Hcl | 38 | 28 |
| Ezetimibe | Ezetimibe | 37 | 13 |
| Glipizide | Glipizide | 37 | 11 |
| Januvia | Sitagliptin Phosphate | 36 | 12 |
| Levofloxacin | Levofloxacin | 36 | 25 |
| Tresiba Flextouch U-100 | Insulin Degludec | 34 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 32 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | 17 |
| Donepezil Hcl | Donepezil Hcl | 30 | 14 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 16 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 17 |
| Fluconazole | Fluconazole | 18 | 16 |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 17 | 11 |
| Colchicine | Colchicine | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 16 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | 12 |
| Captopril | Captopril | 16 | suppressed |
| Felodipine Er | Felodipine | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 15 |
| Tramadol Hcl | Tramadol Hcl | 16 | 11 |
| Ramipril | Ramipril | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 13 |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 13 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 11 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $316.48 · 13 records | PFIZER INC. | ABRYSVO, COMIRNATY, Cologuard Collection Kit, JARDIANCE, OTEZLA, Ozempic, PREVNAR 20, REPATHA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error